This morning, I woke up early to a sad announcement from Genentech that:
“The Phase III METLung study of onartuzumab (MetMab) in combination with Tarceva in MET-positive, advanced non-small cell lung cancer did not meet its primary endpoint of overall survival in a planned interim analysis. At the recommendation of an independent data monitoring committee, we are voluntarily terminating the trial. Adverse events were similar between the two arms.”
Although the full data isn’t yet available, it will be presented at a future medical conference. My guess is that ESMO in Madrid will be a possibility, if the ASCO deadline has already passed. I’ve been avidly following the concept of MET inhibition in advanced lung cancer for both ArQule’s tivantinib and Genentech’s MetMab (onartuzumab) since the data was first presented at ESMO nearly four years ago. These posts are still available on Pharma Strategy Blog (open access).